1Eckardt KU. Renal failure in liver disease. Intensive Care Med, 1999,25: 5-14. 被引量：1
2Guevara M, Gines P, Sort P, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology, 1998, 27:35-41. 被引量：1
3Gines P, Arroyo V. Is there still a need for the treatment of ascites and its complications. Gut, 2000, 45:588-590. 被引量：1
4Le Moine O, Nauar A, Jagodzinski R, et al. Treatment with terlipressin as a bridge to liver transplantation in a patient with hepatorenal syndrome. Acta Gastro Enterologica Belgica, 1998, 61:268-270. 被引量：1
5Mitzner SR, Stange J, Klammt S, et al. MARS: A new treatment for hepatorenal syndrome. Gastroenterology, 2000, 119: 1799-1800. 被引量：1
7Rossle M, Siegerstetter V, Huber M, et al. The first decade of the transjugular intrahepatic portosystemic shunt (TIPS): state of the art.Liver, 1998, 18:73-89. 被引量：1
8Guevara M, Gines P, Carlos B J, et al. Transjugular intrahepatic por tosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology, 1998, 28:416-422. 被引量：1
9Laffi G, La Villa G, Pinzani M, et al. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol, 1997,17:530-548. 被引量：1
